Switching Magnetism and Superconductivity with Spin-Polarized Current in Iron-Based Superconductor

We have explored a new mechanism for switching magnetism and superconductivity in a magnetically frustrated iron-based superconductor using spin-polarized scanning tunneling microscopy (SPSTM). Our SPSTM study on single crystal Sr$_2$VO$_3$FeAs shows that a spin-polarized tunneling current can switch the Fe-layer magnetism into a non-trivial $C_4$ (2$\times$2) order, not achievable by thermal excitation with unpolarized current. Our tunneling spectroscopy study shows that the induced $C_4$ (2$\times$2) order has characteristics of plaquette antiferromagnetic order in Fe layer and strongly suppressed superconductivity. Also, thermal agitation beyond the bulk Fe spin ordering temperature erases the $C_4$ state. These results suggest a new possibility of switching local superconductivity by changing the symmetry of magnetic order with spin-polarized and unpolarized tunneling currents in iron-based superconductors.Comment: 33 pages, 16 figure

Star Formation and AGN activity in Galaxies classified using the 1.6 {\mu}m Bump and PAH features at z=0.4−2z = 0.4-2

We have studied the star-formation and AGN activity of massive galaxies in the redshift range $z=0.4-2$, which are detected in a deep survey field using the AKARI InfraRed (IR) astronomical satellite and {\em Subaru} telescope toward the North Ecliptic Pole (NEP). The AKARI/IRC Mid-InfraRed (MIR) multiband photometry is used to trace their star-forming activities with the Polycyclic-Aromatic Hydrocarbon (PAH) emissions, which is also used to distinguish star-forming populations from AGN dominated ones and to estimate the Star Formation Rate (SFR) derived from their total emitting IR (TIR) luminosities. In combination with analyses of their stellar components, we have studied the MIR SED features of star-forming and AGN-harboring galaxies.Comment: 45 pages and 63 figures, will be published in PASJ Vol.64 No.

Cystatin C as an Early Biomarker of Nephropathy in Patients with Type 2 Diabetes

This study was done to evaluate clinical usefulness of cystatin C levels of serum and urine in predicting renal impairment in normoalbuminuric patients with type 2 diabetes and to evaluate the association between albuminuria and serum/urine cystatin C. Type 2 diabetic patients (n = 332) with normoalbuminuria (n = 210), microalbuminuria (n = 83) and macroalbuminuria (n = 42) were enrolled. Creatinine, urinary albumin levels, serum/urine cystatin C and estimated glomerular filtration rate (eGFR by MDRD [Modification of Diet in Renal Disease] and CKD-EPI [Chronic Kidney Disease Epidemiology Collaboration] equations) were determined. The cystatin C levels of serum and urine increased with increasing degree of albuminuria, reaching higher levels in macroalbuminuric patients (P < 0.001). In multiple regression analysis, serum cystatin C was affected by C-reactive protein (CRP), sex, albumin-creatinine ratio (ACR) and eGFR. Urine cystatin C was affected by triglyceride, age, eGFR and ACR. In multivariate logistic analysis, cystatin C levels of serum and urine were identified as independent factors associated with eGFR < 60 mL/min/1.73 m2 estimated by MDRD equation in patients with normoalbuminuria. On the other hand, eGFR < 60 mL/min/1.73 m2 estimated by CKD-EPI equation was independently associated with low level of high-density lipoprotein in normoalbuminuric patients. The cystatin C levels of serum and urine could be useful markers for renal dysfunction in type 2 diabetic patients with normoalbuminuria

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

Background: Short-term treatment for people with type 2 diabetes using a low dose of the selective endothelin A receptor antagonist atrasentan reduces albuminuria without causing significant sodium retention. We report the long-term effects of treatment with atrasentan on major renal outcomes. Methods: We did this double-blind, randomised, placebo-controlled trial at 689 sites in 41 countries. We enrolled adults aged 18–85 years with type 2 diabetes, estimated glomerular filtration rate (eGFR)25–75 mL/min per 1·73 m 2 of body surface area, and a urine albumin-to-creatinine ratio (UACR)of 300–5000 mg/g who had received maximum labelled or tolerated renin–angiotensin system inhibition for at least 4 weeks. Participants were given atrasentan 0·75 mg orally daily during an enrichment period before random group assignment. Those with a UACR decrease of at least 30% with no substantial fluid retention during the enrichment period (responders)were included in the double-blind treatment period. Responders were randomly assigned to receive either atrasentan 0·75 mg orally daily or placebo. All patients and investigators were masked to treatment assignment. The primary endpoint was a composite of doubling of serum creatinine (sustained for ≥30 days)or end-stage kidney disease (eGFR <15 mL/min per 1·73 m 2 sustained for ≥90 days, chronic dialysis for ≥90 days, kidney transplantation, or death from kidney failure)in the intention-to-treat population of all responders. Safety was assessed in all patients who received at least one dose of their assigned study treatment. The study is registered with ClinicalTrials.gov, number NCT01858532. Findings: Between May 17, 2013, and July 13, 2017, 11 087 patients were screened; 5117 entered the enrichment period, and 4711 completed the enrichment period. Of these, 2648 patients were responders and were randomly assigned to the atrasentan group (n=1325)or placebo group (n=1323). Median follow-up was 2·2 years (IQR 1·4–2·9). 79 (6·0%)of 1325 patients in the atrasentan group and 105 (7·9%)of 1323 in the placebo group had a primary composite renal endpoint event (hazard ratio [HR]0·65 [95% CI 0·49–0·88]; p=0·0047). Fluid retention and anaemia adverse events, which have been previously attributed to endothelin receptor antagonists, were more frequent in the atrasentan group than in the placebo group. Hospital admission for heart failure occurred in 47 (3·5%)of 1325 patients in the atrasentan group and 34 (2·6%)of 1323 patients in the placebo group (HR 1·33 [95% CI 0·85–2·07]; p=0·208). 58 (4·4%)patients in the atrasentan group and 52 (3·9%)in the placebo group died (HR 1·09 [95% CI 0·75–1·59]; p=0·65). Interpretation: Atrasentan reduced the risk of renal events in patients with diabetes and chronic kidney disease who were selected to optimise efficacy and safety. These data support a potential role for selective endothelin receptor antagonists in protecting renal function in patients with type 2 diabetes at high risk of developing end-stage kidney disease. Funding: AbbVie

Spin annihilations of and spin sifters for transverse electric and transverse magnetic waves in co- and counter-rotations

This study is motivated in part to better understand multiplexing in wireless communications, which employs photons carrying varying angular momenta. In particular, we examine both transverse electric (TE) and transverse magnetic (TM) waves in either co-rotations or counter-rotations. To this goal, we analyze both Poynting-vector flows and orbital and spin parts of the energy flow density for the combined fields. Consequently, we find not only enhancements but also cancellations between the two modes. To our surprise, the photon spins in the azimuthal direction exhibit a complete annihilation for the counter-rotational case even if the intensities of the colliding waves are of different magnitudes. In contrast, the orbital flow density disappears only if the two intensities satisfy a certain ratio. In addition, the concepts of spin sifters and enantiomer sorting are illustrated

Optical chirality exhibited by two axially propagating electromagnetic waves in counter-rotations

<div><p>The optical chirality of two axially propagating electromagnetic waves is investigated. These two waves of different nature are in counter-rotations, thereby being non-plane waves. From the resulting spatial distributions of energy and chirality, we find not only enhancements but also cancellations due to the interferences in these hybrid waves. In addition, the roles of the axial wave number and interference phase are illustrated by introducing a proper figure of merit for relevant device performances.</p></div

Phase Formation Behavior and Thermoelectric Transport Properties of P-Type YbxFe3CoSb12 Prepared by Melt Spinning and Spark Plasma Sintering

Formation of multiple phases is considered an effective approach for enhancing the performance of thermoelectric materials since it can reduce the thermal conductivity and improve the power factor. Herein, we report the in-situ generation of a submicron-scale (~500 nm) heterograin structure in p-type Yb-filled (Fe,Co)4Sb12 skutterudites during the melt spinning process. Mixed grains of YbxFe3&minus;yCo1+ySb12 and YbzFe3+yCo1&minus;ySb12 were formed in melt spun ribbons due to uneven distribution of cations. By the formation of interfaces between two different grains, the power factor was enhanced due to the formation of an energy barrier for carrier transport, and simultaneously the lattice thermal conductivity was reduced due to the intensified boundary phonon scattering. A high thermoelectric figure of merit zT of 0.66 was obtained at 700 K

Salient Features of Monomeric Alpha-Synuclein Revealed by NMR Spectroscopy

Elucidating the structural details of proteins is highly valuable and important for the proper understanding of protein function. In the case of intrinsically disordered proteins (IDPs), however, obtaining the structural details is quite challenging, as the traditional structural biology tools have only limited use. Nuclear magnetic resonance (NMR) is a unique experimental tool that provides ensemble conformations of IDPs at atomic resolution, and when studying IDPs, a slightly different experimental strategy needs to be employed than the one used for globular proteins. We address this point by reviewing many NMR investigations carried out on the α-synuclein protein, the aggregation of which is strongly correlated with Parkinson’s disease